Introduction

MHC class I-restricted cytotoxic T lymphocytes (CTL) protect
HBc protein into the secreted HBe protein. The HBe protein has a translocating signal sequence of 19 amino acids that against many virus infections. CD8 ϩ CTL specific for different hepatitis B virus (HBV) gene products have been isolated targets it to the secretory pathway. The P22.5 protein is posttranslationally modified in the lumen of the endoplasmic from patients with HBV infection (reviewed in 1). An important immunogenic gene product of HBV is the hepatitis B core reticulum (ER). Removal of part of the signal sequence and a C-terminal truncation yield the secreted 17 kDa (P17) protein antigen (HBcAg). HBc protein is a cytosolic 21 kDa (P21) protein that self-assembles into 34 nm particles which expose with e antigen activity (HBeAg). In mice class II-restricted T cell epitopes of HBc/eAg have been mapped (2,3). We have HBcAg. The HBc sequence is preceded in-frame by a signal sequence, the so-called pre-core sequence, which converts recently reported the identification of a class I (K b )-restricted HBc/eAg epitope (4). A therapeutic lipopeptide vaccine based into the XhoI site of pBluescript IISK ϩ to generate pBlue-e ∆ . Sequence analysis revealed the expected mutation but no on a human class I-restricted HBcAg epitope has been other mutations in the gene. The XhoI fragment from pBlueproposed for the treatment of chronic HBV infection (5).
e ∆ was ligated into SalI-digested pCMV-1 to generate the In DNA vaccination, plasmid DNA is injected and transiently construct pCMV-1/e ∆ . Transient transfection studies demonexpressed in cells of the skin (6-9) or the muscle (10) (11) (12) .
strated that HBcAg produced in pCMV-1/c-transfected cells DNA immunization primes responses against viruses (11) (12) (13) (14) (15) (16) (17) remains largely associated with the cells, while most of the and parasites (18, 19) . Intramuscular inoculation of expression HBeAg produced by pCMV-1/e-and pCMV-1/e ∆ -transfected plasmid DNA efficiently primes MHC class I-restricted CTL cells was secreted into the supernatant (data not shown). responses (12, 15, 18) . We have reported the priming of class HBeAg expressed from the vector pCMV-1/e ∆ was indistin-I-restricted CTL responses to the hepatitis B surface antigen guishable from HBeAg expressed from pCMV-1/e (data not (HBsAg) and to HBc/eAg (4, [20] [21] [22] [23] [24] [25] Table 1 were synthesized in an Applied Biosystems We have described the construction of the vector pCMV-1 peptide synthesizer model 431A and purified by reversefrom plasmid pSBC-1 (26) , and the insertion of the HBcAgphase HPLC. Peptides were dissolved in a 70% acetonitrile/ and HBeAg-encoding genes into pCMV-1 to generate the 0.1% TFA solution at a concentrations of 20 mg/ml and diluted constructs pCMV-1/c and pCMV-1/e (4). The gene fragment with culture medium for use. encoding the HBeAg with a mutation of the internal start Nucleic acid immunization codon (ATG to ATA) was amplified from a vaccinia recombinant vector kindly provided by H.-J. Schlicht (27) using HBeWe injected 50 µl PBS containing 1 µg/µl plasmid DNA into each regenerating tibialis anterior muscle 5 days after the specific primers (4). The amplification product was cloned 
Peptides were derived from the hepatitis B virus core sequence. The amino acid are shown in the usual one-letter abbreviation. The K dspecific anchor motif is in bold type. The K d -restricted epitope of HBcAg/HBeAg is in italic type.
injection of cardiotoxin (Latoxan, Rosans, France) as previcalculated as [(experimental release -spontaneous release)/ (total release -spontaneous release)] ϫ 100. Total counts ously described (10). The cardiotoxin pretreatment is not critical but enhances CTL priming in most experiments 2-to were measured by resuspending target cells. Spontaneously released counts were always Ͻ20% of the total counts. Data 4-fold (23) . All mice received bilateral intramuscular injections once. Spleen cells were obtained from immunized mice 1-4
shown are the mean of triplicate cultures. The SD of triplicates was always Ͻ20% of the mean. The data shown were obtained weeks post-immunization.
with CTL populations re-stimulated in vitro once for 5-7 days.
Cytotoxicity assay
Following repeated in vitro re-stimulations of bulk CTL lines, their cytolytic reactivity usually increased. Spleen cells from immunized or non-immunized (control) mice were suspended in α-MEM tissue culture medium suppleDetermination of serum antibody levels mented with 10 mM HEPES buffer, 5ϫ10 -5 M 2-mercaptoethanol, antibiotics and 10% v/v FCS (Pan Systems, Anti-HBc antibodies were detected in mouse sera using the Aidenbach, Germany). Then, 3ϫ10 7 responder cells were co-CORE anti-HBc kit (no. 2259-20; Abbott). Concentrations of cultured with 1.5ϫ10 6 syngeneic transfectants (irradiated with anti-HBc were standardized against a reference standard 20,000 rad) in 10 ml medium in upright 25 cm 2 tissue culture of the Paul-Ehrlich-Institute (Langen, Germany). Anti-HBe flasks in a humidified atmosphere/7% CO 2 at 37°C. The antibody titers in sera of DNA-immunized mice were determedium was supplemented with 3% v/v of a rat spleen cellmined using the IMX anti-HBe assay (Abbott). This assay was conditioned medium as a source of growth factors. This standardized using a reference from the Paul Ehrlich Institute. conditioned medium was obtained by culturing 4 ϫ 10 6 rat spleen cells/ml for 24 h in medium/5% v/v FCS with 3 µg Results concanavalin A/ml. To determine the restriction specificity of the HBcAg/HBeAg-specific CTL from H-2 d mice, blocking
HBcAg-and HBeAg-expressing transfectants shown). In RBL5/c cells, HBcAg was present exclusively in cell lysates, but not in supernatants. In P815/c cells, HBcAg Cytotoxic effector populations were harvested after varying intervals of in vitro culture and washed twice. Serial dilutions was found predominantly in the cell lysate, but low amounts of core antigen were reproducibly found in the supernatant. of effector cells were cultured with 2ϫ10 3 51 Cr-labeled targets in 200 µl round-bottom wells. Specific cytolytic activity of
In pBMG/HBe-transfected P815/e and RBL5/e cells, HBeAg was found predominantly in the supernatant; only low amounts cells was tested in short-term 51 Cr-release assays against transfected or peptide-pulsed targets and compared with of the secreted form of the core antigen were present in cell lysates (data not shown). Similar data were obtained in non-transfected/non-pulsed controls. After a 4 h incubation at 37°C, 100 µl of supernatant was collected for immunoprecipitation studies using a polyclonal HBcAgspecific antiserum. γ-radiation counting. The percentage specific release was 
Antibody response of mice immunized with pCMV-1/c or pCMV-1/e plasmid DNA
BALB/c (H-2 d ), C57BL/6 (H-2 b ) or F 1 (BALB/cϫC57BL/6) mice were immunized by a single injection of 100 µg pCMV-1/c or pCMV-1/e plasmid DNA into the regenerating muscle. All animals immunized with pCMV-1/c plasmid DNA developed HBc-specific serum antibody titers detectable in an ELISA ( Fig. 2B ; data not shown). Mice immunized with recombinant HBcAg particles (without adjuvants) also developed HBcspecific serum antibody titers which were always lower than those in DNA-immunized mice (Fig. 2C ). Mice immunized with pCMV-1/e plasmid DNA developed anti-HBe serum antibody titers (Fig. 2E) . The serum antibody response usually became detectable in the third week post-vaccination and increased for the following 3-6 weeks. In contrast, the CTL response was always detectable from 5 days until Ͼ3 months postvaccination. DNA vaccination of BALB/c, C57BL/6 or F 1 mice precursors by DNA immunization was required to generate cytotoxic effector cells. In mixed lymphocyte tumor culture cells primed by pCMV-1/e DNA were re-stimulated with P815/ e transfectants expressing the secreted form of the core (MLTC) with mixed (unprimed and primed) CD4 ϩ and CD8 ϩ T cell populations, CD4 ϩ T cells primed in vivo by DNA protein (HBeAg). In vivo primed and in vitro re-stimulated CTL populations lysed syngeneic targets expressing the immunization did not support the in vitro priming of naive CD8 ϩ T cells by co-culture with transfectants (data not shown). respective antigen (Fig. 3) by HBcAg-primed CTL (Fig. 4) . Similar data were found in either with HBcAg-expressing P815/c transfectants or with HBeAg-expressing P815/e transfectants. The cytotoxic assays with HBeAg-primed CTL recognizing the HBeAgexpressing P815/e targets (Fig. 4) 6 and data not shown). The amount of DNA used in vaccination A library of overlapping synthetic peptides of the HBV core antigen was used to map the epitope recognized by CTL was titrated by injecting 100, 20 or 4 µg/mouse (Table 2 ). These data confirmed that constructs encoding the intracellufrom pCMV-1/c or pCMV-1/e immunized H-2 d mice (4). Only P815 cells pulsed with 10 -6 M of a peptide representing lar form (HBcAg) or the secreted (HBeAg) form of the core antigen elicited CTL responses when 100 or 20 µg of the residues 82-101 of HBcAg were lysed by short-time CTL lines (12-25% specific lysis at an effector:target ratio of 40).
plasmid DNA were injected. Similar data were obtained when pCMV-1/e or pCMV-1/e ∆ vector DNA were injected. Hence, Fine mapping of the epitope identified it as the 9mer peptide SYVNTNMGL spanning residues 87-95 of HBcAg (Table 1 processing and/or presentation of the K d -binding peptide from cytoplasmic/nuclear HBcAg or secreted HBeAg was and (Fig. 1) . We tested if two CTL populations specific for either the K d -restricted epitope or the K b -restricted epitope residues the sequence of the 8mer epitope of HBcAg recognized in the context of K b (Fig. 1) .
are co-primed in (Fig. 7A and B) and of H-2 d mice against Table 1. the K d -restricted epitope ( Fig. 7C and D) . DNA vaccination Natural processing and presentation of two overlapping class I-restricted epitopes of F 1 mice thus primes distinct CTL populations with different restriction specificities that recognize overlapping peptides DNA immunization of C57BL/6 (H-2 b ) mice elicits K b -restricted efficiently processed from an intracellular or a secreted pro-CTL responses against the 8mer epitope MGLKFRQL tein antigen.
(HBcAg 93-100 ) of HBcAg/HBeAg (4). This epitope stimulates a CTL response when mice are immunized with HBcAg-or with HBeAg-encoding expression plasmids. This epitope is Discussion generated during natural processing of the secreted form Potent stimulation of CTL responses by DNA immunization (HBeAg) and the cytoplasmic form (HBcAg) of the core antigen. The 8mer epitope is of the expected length, contains The study confirms that DNA vaccination is a potent technique the K b -specific anchor motif (30) In this paper, we have mapped the K d -restricted 9mer HBcAg core particles by different routes. This is in contrast HBcAg 87-95 peptide SYVNTNMGL as a further CTL epitope. to other 'virus-like particle' systems in which CTL responses It overlaps with the K b -restricted epitope by three amino acid can be primed by injecting low doses of lipoprotein particles residues. The efficiency of antigen processing seems to without adjuvants. This has been shown in the HBsAg system depend on intrinsic qualities of an epitope and its location (20) (21) (22) 24, (31) (32) (33) (34) , in the HIV gag system (35) and in the Ty within the protein. Proteolytic degradation of HBcAg/HBeAg 'virus-like particle' system (36,37). It is unknown why HBcAg to generate these epitopes may involve one or multiple steps. particles have only a low immunogenicity for CTL precursors.
Processing could generate a 14mer (or larger) peptide, that In some antigen systems induction of a class I-restricted is transported through the TAP, binds to MHC class I molecules CTL response may be 'difficult'. Although CTL can recognize and is subsequently trimmed to the appropriate size. Alternatpeptide epitopes of these antigens binding to MHC class I ively, different proteolytic cleavages could generate two differmolecules with high affinity and can mediate different effector ent peptides that each contains one of the two epitopes. functions in vivo, they are difficult to prime with traditional vaccination approaches. We have described this with the Secreted and intracellular forms of the HBV core protein are HBsAg in H-2 b mice (25) and with the SV40 T antigen in Hefficiently processed for class I-restricted presentation 2 d mice (38) . Once induced, such T cell response may have a considerable prophylactic or therapeutic potential. This
The pre-core region of HBV contains two alternative ATG translation initiation codons. The precursor for the secreted observation makes DNA vaccination an interesting option in the immunotherapy of cancer and persisting infections.
P22.5 form of the core protein is translated from the first ATG;
Vaccination with plasmids encoding HBcAg or HbeAg 1209 a Titrated amounts of expression plasmid DNA encoding the intracellular (pCMV-1/c) or the secreted (pCMV-1/e or pCMV-1/e ∆ ) form of the core protein were injected intramuscularly into BALB/c mice b The cytotoxic response was read out against P815/c targets or P815 targets at the indicated effector/target ratios the intracellular form of the core protein is translated from the data indicate that generation of peptides from secreted and intracellular proteins for loading to MHC class I molecules is second ATG. To exclude the possibility that low levels of HBcAg are translated from the second ATG during biosynequally efficient. The site of processing of secreted HBeAg, and the site of loading of the generated peptides to K b and thesis of P22.5 from the first ATG, we mutated the second ATG. From this construct (pCMV-1/e ∆ ), only secreted HBeAg K d molecules, remains to be elucidated. Cytosolic degradation of proteins seems to be the major source for peptides can be expressed. Injection of this plasmid primed K band K d -restricted CTL to HBc/eAg efficiently ( Table 2) . The presented by MHC class I molecules (39) . The site of processing of secreted proteins for recognition by CTL is uncersecreted form of the core antigen can therefore be processed for class I-restricted peptide presentation.
tain. Most secreted proteins, including the P22.5 protein, are co-translationally translocated into the ER lumen during We observed no differences in the efficiency of CTL priming by plasmid DNA encoding HBeAg or HBcAg and we found biosynthesis. In peptide transporter (TAP)-deficient cell lines, processing within the ER lumen has been shown to generate no differences in the efficiency of K b -or K d -restricted presentation of the HBcAg/HBeAg epitopes by transfectants. These MHC class I-binding peptides, mostly derived from cleaved or peptides from the ER lumen into the cytosol may feed them into a pool that is available for TAP-dependent loading on nascent class I molecules (41, 42) . Low-frequency failure of References the signal sequence-containing polypeptide to engage the
